Co důležitého přináší čtvrtá definice infarktu myokardu?

Jan F. Vojáček

Interv Akut Kardiol. 2018;17(4):198-200  

Percutaneous pulmonary valve implantation

Ondřej Materna, Petr Tax, Petra Antonová, Jana Rubáčková Popelová, Jan Janoušek, Oleg Reich

Interv Akut Kardiol. 2018;17(4):202-205 | DOI: 10.36290/kar.2018.027  

Between 12/2011 and 7/2018, percutaneous pulmonary valve implantation (PPVI) was performed in 23 patients (8 women, 15 men).In 22 patients, the Melody TPV (Medtronic) valve was used. The Sapien valve (Edwards Lifescience) was implanted in one patient.The median age at implantation was 19.0 years (IQR 15.4–27.1). The median follow-up duration was 2.6 years (IQR 1.1–4.5, maximum5.9 years). There was no death during the whole follow-up period. PPVI resulted in an immediate improvement in the right ventricleto aortic pressure ratio and in a decrease in the right ventricle to pulmonary artery pressure gradient, p < 0.001. Echocardiographicmeasurements...

Efficacy of seal-wing paclitaxel-eluting balloon catheters in the treatment of drug-eluting stent restenosis

Leoš Pleva, Pavel Kukla, Jana Zapletalová, Ota Hlinomaz

Interv Akut Kardiol. 2018;17(4):206-210 | DOI: 10.36290/kar.2018.022  

Aim: Our study aimed to compare the efficacy of seal-wing paclitaxel-eluting balloon catheters (PEB) for treating drug eluting stent restenosis (DES-ISR). Methods: We enrolled 17 patients with 19 DES-ISR lesions. The control group comprised of 64 patients with bare-metal stent restenosis (BMS-ISR) from the seal-wing PEB arm of a previous TIS study. The primary end-point was 12-month in-segment late lumen loss (LLL). Secondary end-points included incidence of binary in-stent restenosis, 12-month major adverse cardiac events (MACE) and target vessel revascularisation (TVR). Results: Compared to BMS-ISR, seal-wing PEB used for DES-ISR treatment was associated...

Treating hypercholesterolaemia with evolocumab

Richard Češka, Michaela Šnejdrlová, Michal Vrablík, Tereza Altschmiedová, Tomáš Štulc

Interv Akut Kardiol. 2018;17(4):212-217 | DOI: 10.36290/kar.2018.057  

Cardiovascular diseases (CVDs) still remain a crucial problem for all western countries as well as for those countries that followtheir pattern of economic development. Even though the treatment of CVDs has gone through enormous success in recentyears, risk factor control is of no less (or even more) importance. Among risk factors, LDL-C plays an essential role as a primarygoal of treatment. Nonpharmacological measures with an emphasis on lifestyle modification are the mainstay of treatment. Ina high proportion of patients, however, pharmacological treatment must be used. Statin therapy is a cornerstone in treatment,with ezetimib being added in combination...

Overview of the new guidelines on myocardial revascularization

Michael Želízko

Interv Akut Kardiol. 2018;17(4):219-224 | DOI: 10.36290/kar.2018.058  

The 2018 ESC/EACTS Guidelines on myocardial revascularization are the guidelines’ third version, having 70 pages of text and atotal of 786 citations. Along with the main document, Supplementary data are available with another 19 pages of text and 122citations. The article deals with the guidelines published, briefly summarizing the main principles in the indications of myocardialrevascularization in patients with both acute and chronic forms of CAD and in specific patient subgroups.

Intermittent high-grade atrioventricular block as a rare extra-articular manifestation of rheumatoid arthritis

Marek Hozman, Alexandr Schee

Interv Akut Kardiol. 2018;17(4):225-227 | DOI: 10.36290/kar.2018.059  

High-grade or complete atrioventricular (AV) block is a rare extraarticular manifestation of rheumatoid arthritis (RA). We reporta case of a 34-year-old patient with recurrent syncope. She had been receiving treatment for RA for 17 years. Ambulatory ECGmonitoring revealed an intermittent 2 : 1 and 3 : 1 AV block. No other causes of the conduction system disorder have been found.The patient underwent DDD-R permanent pacemaker implantation.

Acute anterior myocardial infarction in a 35-years-old woman caused by LAD take-off occlusion complicated by acute stent thrombosis

Zdeněk Coufal

Interv Akut Kardiol. 2018;17(4):229-233 | DOI: 10.36290/kar.2018.060  

Acute myocardial infarction in very young people aged up to 40 years occurs in about 2% of all patients with MI and is verysporadic in women. Most of these individuals are smokers. We present a case report of acute anterior myocardial infarction ina 35 years old woman caused by LAD take-off occlusion complicated by acute stent thrombosis.

Akutní a intervenční kardiologie na kongresu Evropské kardiologické společnosti v Mnichově 2018

Stanislav Šimek

Interv Akut Kardiol. 2018;17(4):248-250  

Anti-inflammatory therapy for atherosclerosis. Results of the CANTOS trial

Jaromír Hradec

Interv Akut Kardiol. 2018;17(4):235-238  

Several hypotheses have been postulated on the development of atherosclerosis. The most elaborate of them is the lipidtheory the validity of which has been supported by the results of many clinical trials of hypolipidemic drugs. There is nodoubt that vessel wall inflammation plays an important role in the development of atherosclerosis, but so far no directevidence has existed for the validity of the inflammatory hypothesis. In the CANTOS clinical trial, three doses of the humanmonoclonal anti-interleukin-1β antibody canakinumab were tested versus placebo in a randomized fashion in postmyocardialinfarction patients who simultaneously had increased...

What has the REVEAL trial shown?

Jan Bultas, Debora Karetová

Interv Akut Kardiol. 2018;17(4):239-242  

The REVEAL trial with anacetrapib, a CETP (cholesteryl ester transfer protein) inhibitor, has been one of the largest “lipid” studiesconducted so far. Its aim was to confirm the hypothesis that an increase in high-density lipoprotein (HDL) cholesterol will reducethe cardiovascular risk. The CETP transporter glycoprotein transfers cholesterol esters and triglycerides from HDL to the liver and toatherogenic lipoproteins. The result is an increase in HDL cholesterol and a variable decrease in low-density lipoprotein (LDL) cholesterol.On the one hand, this effect is positive – i.e. a decreased concentration of cholesterol esters in atherogenic...

The RELAX-AHF-2 Trial: RELAXin in Acute Heart Failure-2

Lenka Špinarová, Jiří Špinar

Interv Akut Kardiol. 2018;17(4):243-244  

Serelaxin is a recombinant form of human relaxin-2 with favourable haemodynamic properties. The RELAX-AHF trial raised hopethat this agent could affect the mortality rates in patients with acute decompensated heart failure. The RELAX-AHF-2 trial wasintended to confirm this assumption. The trial studied the administration of serelaxin against placebo in patients with acute heartfailure. After adding this agent to the standard medication for heart failure, there was no clinical improvement by day 5 of hospitalizationas well as no reduction in the 180-day cardiovascular mortality rate in the patients. Likewise, there was no reduction inthe overall 180-day...

GLOBAL LEADERS – paving the way for better antithrombotic treatment?

Ivo Varvařovský

Interv Akut Kardiol. 2018;17(4):246-247  

The GLOBAL LEADERS trial failed to show superiority of short and intensive dual antiplatelet therapy followed by ticagrelor monotherapyover convention dual antiplatelet treatment after percutansous coronary angioplasty. The results of this study could layfoundations for the next research.